These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28243090)

  • 1. An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation.
    Nakamura I; Ichimura E; Goda R; Hayashi H; Mashiba H; Nagai D; Yokoyama H; Onda T; Masuda A
    Int J Nanomedicine; 2017; 12():1293-1304. PubMed ID: 28243090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.
    Emoto S; Yamaguchi H; Kishikawa J; Yamashita H; Ishigami H; Kitayama J
    Cancer Sci; 2012 Jul; 103(7):1304-10. PubMed ID: 22429777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel.
    Hamaguchi T; Matsumura Y; Suzuki M; Shimizu K; Goda R; Nakamura I; Nakatomi I; Yokoyama M; Kataoka K; Kakizoe T
    Br J Cancer; 2005 Apr; 92(7):1240-6. PubMed ID: 15785749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel.
    Negishi T; Koizumi F; Uchino H; Kuroda J; Kawaguchi T; Naito S; Matsumura Y
    Br J Cancer; 2006 Sep; 95(5):601-6. PubMed ID: 16909136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation.
    Hamaguchi T; Kato K; Yasui H; Morizane C; Ikeda M; Ueno H; Muro K; Yamada Y; Okusaka T; Shirao K; Shimada Y; Nakahama H; Matsumura Y
    Br J Cancer; 2007 Jul; 97(2):170-6. PubMed ID: 17595665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyester Nanoparticle Encapsulation Mitigates Paclitaxel-Induced Peripheral Neuropathy.
    Ganugula R; Deng M; Arora M; Pan HL; Kumar MNVR
    ACS Chem Neurosci; 2019 Mar; 10(3):1801-1812. PubMed ID: 30609902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer.
    Kosaka Y; Saeki T; Takano T; Aruga T; Yamashita T; Masuda N; Koibuchi Y; Osaki A; Watanabe J; Suzuki R
    Int J Nanomedicine; 2022; 17():4567-4578. PubMed ID: 36217496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer.
    Kato K; Chin K; Yoshikawa T; Yamaguchi K; Tsuji Y; Esaki T; Sakai K; Kimura M; Hamaguchi T; Shimada Y; Matsumura Y; Ikeda R
    Invest New Drugs; 2012 Aug; 30(4):1621-7. PubMed ID: 21728023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation, optimization, hemocompatibility and pharmacokinetic evaluation of PLGA nanoparticles containing paclitaxel.
    Mittal P; Vardhan H; Ajmal G; Bonde GV; Kapoor R; Mittal A; Mishra B
    Drug Dev Ind Pharm; 2019 Mar; 45(3):365-378. PubMed ID: 30394795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ionically fixed polymeric nanoparticles as a novel drug carrier.
    Lee SW; Chang DH; Shim MS; Kim BO; Kim SO; Seo MH
    Pharm Res; 2007 Aug; 24(8):1508-16. PubMed ID: 17380262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat.
    Peters CM; Jimenez-Andrade JM; Kuskowski MA; Ghilardi JR; Mantyh PW
    Brain Res; 2007 Sep; 1168():46-59. PubMed ID: 17698044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with pluronic P105/poly(caprolactone) copolymers.
    Wang Y; Li Y; Wang Q; Fang X
    Pharmazie; 2008 Jun; 63(6):446-52. PubMed ID: 18604988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
    Fujiwara Y; Mukai H; Saeki T; Ro J; Lin YC; Nagai SE; Lee KS; Watanabe J; Ohtani S; Kim SB; Kuroi K; Tsugawa K; Tokuda Y; Iwata H; Park YH; Yang Y; Nambu Y
    Br J Cancer; 2019 Mar; 120(5):475-480. PubMed ID: 30745582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
    Battogtokh G; Kang JH; Ko YT
    Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel-loaded PCL-TPGS nanoparticles: in vitro and in vivo performance compared with Abraxane®.
    Bernabeu E; Helguera G; Legaspi MJ; Gonzalez L; Hocht C; Taira C; Chiappetta DA
    Colloids Surf B Biointerfaces; 2014 Jan; 113():43-50. PubMed ID: 24060929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mixed polymeric micelle for co-delivery of paclitaxel and retinoic acid and overcoming multidrug resistance: synthesis, characterization, cytotoxicity, and pharmacokinetic evaluation.
    Emami J; Rezazadeh M; Mashayekhi M; Rostami M; Jahanian-Najafabadi A
    Drug Dev Ind Pharm; 2018 May; 44(5):729-740. PubMed ID: 29235901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes.
    Jiménez-López J; Bravo-Caparrós I; Cabeza L; Nieto FR; Ortiz R; Perazzoli G; Fernández-Segura E; Cañizares FJ; Baeyens JM; Melguizo C; Prados J
    Biomed Pharmacother; 2021 Jan; 133():111059. PubMed ID: 33378963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
    Zhang T; Luo J; Fu Y; Li H; Ding R; Gong T; Zhang Z
    Colloids Surf B Biointerfaces; 2017 Feb; 150():89-97. PubMed ID: 27898360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma.
    Gong C; Xie Y; Wu Q; Wang Y; Deng S; Xiong D; Liu L; Xiang M; Qian Z; Wei Y
    Nanoscale; 2012 Sep; 4(19):6004-17. PubMed ID: 22910790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105/L101 mixed polymeric micelles.
    Wang Y; Li Y; Wang Q; Wu J; Fang X
    Yakugaku Zasshi; 2008 Jun; 128(6):941-50. PubMed ID: 18520140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.